Full-dose ifosfamide can be safely administered to outpatients
Cristina Meazza MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Search for more papers by this authorGianni Bisogno MD
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorMichela Casanova MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Search for more papers by this authorIlaria Zanetti
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorModesto Carli MD
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorCorresponding Author
Andrea Ferrari MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, 1-20133 Milano MI, Italy.===Search for more papers by this authorCristina Meazza MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Search for more papers by this authorGianni Bisogno MD
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorMichela Casanova MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Search for more papers by this authorIlaria Zanetti
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorModesto Carli MD
Pediatric Department, Division of Hematology-Oncology, University Hospital of Padova, Padova, Italy
Search for more papers by this authorCorresponding Author
Andrea Ferrari MD
Pediatric Oncology Unit, Istituto Nazionale Tumori, Milano, Italy
Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, 1-20133 Milano MI, Italy.===Search for more papers by this authorAbstract
This report compares a traditional full-dose ifosfamide administration modality (24-hr hyperhydration and mesna infusion) with a simplified 9-hr hyperhydration and mesna infusion for use in outpatients. Acute ifosfamide toxicity was the same, suggesting that ifosfamide could be safely administered to outpatients, reducing the currently-recommended prolonged hyperhydration and mesna uroprotection, thus resulting in shorter hospital stays and consequently lower costs. Pediatr Blood Cancer 2008;50:375–378. © 2006 Wiley-Liss, Inc.
REFERENCES
- 1 Brock N. Oxazaphosphorine cytostatics: Past-present-future. Seventh Cain Memorial Award Lecture. Cancer Res 1989; 49: 1–7.
- 2 Furlant M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003; 65: 2–6.
- 3 Carli M, Passone E, Perilongo G, et al. Ifosfamide in pediatric solid tumors. Oncology 2003; 65: 99–104.
- 4 Dubourg L, Michoudet C, Cochat P, et al. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001; 12: 1615–1623.
- 5 Takamoto S, Sakura N, Yashiki M, et al. Inactivation of acrolein by sodium 2-mercaptoethanesulfonate using headspace-solid-phase microextraction gas chromatography and mass spectrometry. J Chromatogr B 2003; 791: 365–369.
- 6 Takamoto S, Sakura N, Namera A, et al. Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosfamide. J Chromatogr B 2004; 806: 59–63.
- 7 Lind MJ, Ardiet C. Pharmacokinetics of alkylating agents. Cancer Surv 1993; 17: 157–188.
- 8 Cerny T, Castiglione M, Brunner K, et al. Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990; 335: 175.
- 9 Antman KH, Ryan L, Wyllie R, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresactable sarcoma. J Clin Oncol 1989; 7: 126–131.
- 10 Boddy AV, Yule SM, Wyllie R. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995; 5: 785–790.
- 11 Bisogno G, De Bernardi B, Cordero di Montezemolo L. A randomized comparison of ifosfamide administered as continuous or short infusion in children with soft tissue sarcoma. Med Pediatr Oncol 2001; 37: 181. abstract O74.
- 12 Skinner R, Cole M, Pearson ADJ, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993; 11: 173–190.
- 13 Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41: 190–197.
- 14 Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after ifosfamide treatment in children. A UKCCSG late effects group study. British J Cancer 2000; 82: 1636–1645.
- 15 Aleska K, Woodland C, Koren G. Young age and risk for ifosfamide-induced neophrotoxicity: A critical review of two opposing studies. Pediatr Nephrol 2001; 16: 1153–1158.
- 16
Rossi R,
Pleyer J,
Schafers P, et al.
Development of ifosfamide-induced nephrotoxicity: Prospective follow-up in 75 patients.
Med Peidatric Oncol
1999;
32:
177–182.
10.1002/(SICI)1096-911X(199903)32:3<177::AID-MPO3>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 17 De Kraker J, Voute PA. Ifosfamide, mesna and vincristine in pediatric oncology. Cancer Treat Rev 1983; 10: 165–166.
- 18 Pinkerton CR, Rogers H, James C, et al. A phase II study of ifosfamide in children with recurrent solid tumors. Cancer Chemother Pharmacol 1985; 15: 258–262.
